Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1984-7-13
|
pubmed:abstractText |
Epirubicin , a stereoisomer of doxorubicin with suggested lower potential for cardiotoxicity in animal tumor systems, was evaluated in a disease-oriented phase II trial in non-small cell lung cancer. The drug was given as a direct i.v. injection of 90 mg/m2 repeated every 3 weeks. Four partial remissions were observed among 75 evaluable patients. Forty-two of the 75 patients had received no prior chemotherapy. The predicted true response rate is equal to 5% (0.2-10%). Leucopenia (75% of patients), gastrointestinal disturbances (76% of patients) and alopecia (53% of patients) were common side-effects observed. Four patients had cardiac abnormalities after treatment with epirubicin (one sinustachycardia , two premature beats, one biopsy-proven cardiomyopathy with congestive heart failure). One patient developed a peripheral neuropathy possibly related to epirubicin . We conclude that epirubicin in the present dose and schedule is an inactive agent in patients with non-small cell lung cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0277-5379
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
495-9
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:6327315-Adenocarcinoma,
pubmed-meshheading:6327315-Aged,
pubmed-meshheading:6327315-Antibiotics, Antineoplastic,
pubmed-meshheading:6327315-Carcinoma, Small Cell,
pubmed-meshheading:6327315-Carcinoma, Squamous Cell,
pubmed-meshheading:6327315-Doxorubicin,
pubmed-meshheading:6327315-Drug Evaluation,
pubmed-meshheading:6327315-Epirubicin,
pubmed-meshheading:6327315-Humans,
pubmed-meshheading:6327315-Lung Neoplasms,
pubmed-meshheading:6327315-Time Factors
|
pubmed:year |
1984
|
pubmed:articleTitle |
Phase II trial of epirubicin in advanced squamous, adeno- and large cell carcinoma of the lung.
|
pubmed:publicationType |
Journal Article
|